PSTI Pluristem Therapeutics, Inc.

1.20
+0  (2%)
Previous Close 1.17
Open 1.17
Price To book 3.80
Market Cap 115.28M
Shares 96,065,000
Volume 124,494
Short Ratio 2.31
Av. Daily Volume 462,882

SEC filingsSee all SEC filings

  1. 10-Q - Quarterly report (Sections 13 or 15(d)) 17582564
  2. 8-K - Current report 17538846
  3. 424B5 - Prospectus (Rule 424(b)(5)) 17537498
  4. 424B5 - Prospectus (Rule 424(b)(5)) 17536594
  5. 8-K - Current report 17529664

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 enrollment to commence 1H 2017.
PLX-PAD (stem cells)
Critical limb ischemia (CLI)
Phase 2 put on clinical hold Jun 2013. Lifted Sept 2013. Enrollment completed May 2016. Data are due late 2017.
PLX-PAD (stem cells)
Intermittent claudication, or IC

Latest News

  1. Pluristem Therapeutics, Inc. :PSTI-US: Earnings Analysis: Q2, 2017 By the Numbers
  2. PLURISTEM THERAPEUTICS INC Financials
  3. Pluristem Therapeutics downgraded by Maxim Group
  4. Pluristem Reports Second Quarter Fiscal 2017 Highlights & Provides Calendar 2017 Outlook
  5. Pluristem reports 2Q loss
  6. Pluristem reports 2Q loss
  7. PLURISTEM THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report
  8. Pluristem Announces Closing of Bought Offering and Underwriter’s Exercise in Full of Over-Allotment Option
  9. PLURISTEM THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E
  10. Pluristem Increases Previously Announced Bought Deal Offering of Common Stock and Warrants to $15,000,000
  11. Pluristem Announces Bought Deal Offering
  12. Flood of News Presents Buying Opportunity
  13. PLURISTEM THERAPEUTICS INC Files SEC form 8-K, Other Events
  14. Pluristem Receives Clearance from Germany to Initiate its Multinational Phase III Trial in Critical Limb Ischemia Targeting Early Conditional Marketing Approval
  15. Pluristem (PSTI) Intermittent Claudication Study Enrolled
  16. Pluristem Completes Patient Enrollment in a Large Multinational Phase II Trial in Intermittent Claudication
  17. Pluristem Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : PSTI-US : January 12, 2017
  18. Pluristem Therapeutics Inc. (PSTI) To Begin CLI Phase III Trial Enrolling Only 250 Patients, With FDA Blessing
  19. PLURISTEM THERAPEUTICS INC Files SEC form 8-K, Other Events
  20. Pluristem shares jump 5.4% premarket as FDA approves trial of treatment for critical limb ischemia

SEC Filings

  1. 10-Q - Quarterly report (Sections 13 or 15(d)) 17582564
  2. 8-K - Current report 17538846
  3. 424B5 - Prospectus (Rule 424(b)(5)) 17537498
  4. 424B5 - Prospectus (Rule 424(b)(5)) 17536594
  5. 8-K - Current report 17529664
  6. 8-K - Current report 17522298
  7. 8-K - Current report 162067906
  8. 8-K - Current report 162060771
  9. 8-K - Current report 161987152
  10. 10-Q - Quarterly report (Sections 13 or 15(d)) 161978138